FR 173657Alternative Names: FK 3657
Latest Information Update: 10 Sep 2003
At a glance
- Originator Fujisawa
- Developer Fujisawa; Nonindustrial source
- Class Analgesics; Anti-inflammatories; Antiasthmatics
- Mechanism of Action Angiogenesis inhibitors; Bradykinin B2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma; Cancer; Ulcerative colitis